WHO ICTRP trial
Phase I and IIa trial for assessment of safety, immunogenicity and efficacy…
NL-OMON30669 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON30669 |
|---|---|
| Public title | Phase I and IIa trial for assessment of safety, immunogenicity and efficacy against sporozoite challenge of the candidate malaria vaccine PfLSA-3-rec. |
| Scientific title | Phase I and IIa trial for assessment of safety, immunogenicity and efficacy against sporozoite challenge of the candidate malaria vaccine PfLSA-3-rec. - LSA-3-rec |
| Primary sponsor | Institut Pasteur |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | malaria; Plasmodium flaciparum infection;10019815;malaria; Plasmodium flaciparum infection |
| Interventions | Subcutaneous administration of the recombinant malaria vaccine PfLSA-3-rec, three times to all volunteers. Intervention arm 1: PfLSA-3-rec with aluminium hydroxide as adjuvant Intervention arm 2: PfLSA-3-rec with Montanide Isa 720 as… |
| Registration date | Apr 10, 2007 |
| Target size | 36 |
| Secondary IDs | 2006-001743-66;NL14715.000.06 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: